Autosomal Dominant Hyperinsulinemic Hypoglycemia Due to SUR1 Deficiency

Autosomal dominant hyperinsulinemic hypoglycemia due to SUR1 deficiency is a genetic condition where the pancreas releases too much insulin, causing low blood sugar (hypoglycemia) that can recur from the newborn period into childhood or even adulthood. “Autosomal dominant” means a single changed copy of the gene can cause the disorder, and it can pass from an affected parent to a child with a 50% chance each pregnancy. “SUR1” is a protein (the sulfonylurea receptor 1) that forms one half of the KATP channel (a potassium channel) in pancreatic beta cells. That channel is made from SUR1 (ABCC8 gene) and Kir6.2 (KCNJ11 gene). The KATP channel acts like a glucose sensor: it helps the cell decide when to secrete insulin. When SUR1 is deficient or malfunctioning, the channel tends to stay closed, the cell behaves as if blood sugar is always high, and insulin is released inappropriately, driving glucose down. In autosomal dominant ABCC8 disease, the clinical picture is often milder than the severe recessive forms, but it can range from very mild to significant; some dominant variants respond to the drug diazoxide, while others do not. Prompt recognition and treatment are critical because repeated hypoglycemia can injure the developing brain. BioMed Central+3NCBI+3Orpha+3

This condition causes repeated low blood sugar because the pancreas releases too much insulin even when blood glucose is low. It is “autosomal dominant,” meaning a single changed copy of the ABCC8 gene (which encodes the SUR1 subunit of the KATP channel) can be enough to cause disease and can run in families. Dominant ABCC8/KCNJ11 forms tend to present later and be milder than the classic recessive neonatal form and often respond to diazoxide, a KATP opener. Mechanistically, SUR1 loss keeps the KATP channel closed, depolarizes beta cells, and triggers insulin release at the wrong times. NCBI+2PMC+2

In healthy beta cells, KATP channels (made of Kir6.2/KCNJ11 and SUR1/ABCC8) open when glucose is low, keeping the cell “quiet” so insulin is not released. In SUR1 deficiency, the channel cannot open properly, so the cell stays “excited” and pushes insulin out even during fasting. Too much insulin suppresses ketones and free fatty acids, removing the brain’s backup fuels, so hypoglycemia can be severe. Lab patterns include inappropriately high insulin/C-peptide during hypoglycemia, low beta-hydroxybutyrate, and low free fatty acids. NCBI

---

Other names

• ABCC8-related hyperinsulinism

• KATP-hyperinsulinism (KATP-HI), autosomal dominant form

• SUR1-deficient hyperinsulinism

• Congenital hyperinsulinism due to ABCC8 (dominant)
  (All refer to the same core problem: pathogenic variants in ABCC8 affecting SUR1 and KATP function.) NCBI+1

---

Types

1) Diazoxide-responsive dominant ABCC8 hyperinsulinism.
Many autosomal dominant SUR1 variants lead to a milder, often diazoxide-responsive form. Diazoxide opens KATP channels and reduces insulin secretion, allowing outpatient management in many children. endotext.org+1

2) Diazoxide-unresponsive dominant ABCC8 hyperinsulinism.
Some dominant SUR1 changes act in a dominant-negative way or disrupt drug binding/gating, producing hypoglycemia not controlled by diazoxide. These children may need other medicines (e.g., octreotide) and careful evaluation to exclude focal disease. PMC+2PubMed+2

3) Age-of-onset variants (neonatal, infant, childhood, adult).
Dominant ABCC8 disease can appear at different ages, from neonatal hypoglycemia to later childhood or even adult-onset with mild fasting or exercise-related episodes. Phenotype depends on the specific variant and its effect on channel gating/trafficking. NCBI+1

4) Diffuse pancreatic involvement (typical for dominant ABCC8).
Dominant ABCC8 disease usually produces diffuse beta-cell over-secretion (all over the pancreas). In congenital hyperinsulinism overall, a focal form exists (a small overactive area) that is often due to a special “two-hit” mechanism with a paternally inherited KATP variant and somatic maternal allele loss; PET-CT with 18F-DOPA is used to find it. This matters mainly to exclude focal disease, which can be cured surgically; most dominant ABCC8 cases are diffuse and managed medically. NCBI+2PubMed+2

---

Causes

In a genetic condition like this, the word “cause” covers why the disease exists (the genetic mechanism) and what provokes or worsens low-glucose episodes in daily life.

Genetic/biologic mechanisms

1. Pathogenic missense variants in ABCC8 that impair SUR1 gating → persistent insulin release. OUP Academic

2. Dominant-negative SUR1 effects (mutant SUR1 disrupts channel made with normal SUR1). OUP Academic

3. Defective SUR1 trafficking to the beta-cell membrane → fewer functional KATP channels. Nature

4. Impaired nucleotide (Mg-ADP/ATP) binding or hydrolysis at SUR1’s NBDs → channel stays closed. OUP Academic

5. Reduced diazoxide binding/effect at SUR1 → medical unresponsiveness in some dominant variants. PMC+1

6. Constitutive beta-cell depolarization from KATP closure → calcium influx and insulin secretion. (Core KATP physiology summarized in reviews.) NCBI

Everyday triggers that precipitate/worsen hypoglycemia in affected people

7. Prolonged fasting (overnight, illness, travel).

8. Intercurrent illness (fever, poor intake, vomiting) that reduces glycogen stores.

9. Strenuous or long-duration exercise without added carbohydrates.

10. High-carbohydrate load followed by a long gap, producing a rebound low in some children.

11. Prematurity or low glycogen reserves in early infancy.

12. Missed meals or delayed feeds, especially in toddlers/young children.

13. Rapid weight loss or restrictive dieting in adolescents/adults.

14. Alcohol consumption (adolescents/adults) that blocks gluconeogenesis.

15. Certain drugs that increase insulin release (e.g., sulfonylureas)—generally avoided.

16. Beta-blockers that mask warning signs of hypoglycemia.

17. Post-operative periods with limited intake or increased metabolic need.

18. Sepsis or serious infection increasing glucose use.

19. Disrupted sleep schedule causing long unplanned fasts (e.g., travel).

20. Poor adherence to prescribed diazoxide/other therapy or diet plans.

(Items are widely accepted precipitating factors for hypoglycemia management in congenital hyperinsulinism and pediatric endocrinology practice; they complement the genetic mechanisms above.) endotext.org

---

Symptoms and signs

1. Jitteriness or tremor when hungry or after long gaps between feeds.

2. Irritability, sweating, pallor, fast heartbeat—classic adrenergic warnings.

3. Poor feeding, vomiting, or lethargy in infants.

4. Seizures or staring spells during lows.

5. Floppiness (hypotonia) or poor responsiveness with severe episodes.

6. Cyanosis or breathing pauses in neonates during profound hypoglycemia.

7. Headaches in older children after exertion or missed meals.

8. Confusion, trouble concentrating, or behavioral change (neuroglycopenia).

9. Visual blurring during lows.

10. Irritability at night/early morning that improves after feeding.

11. Failure to thrive or excessive weight gain from frequent high-calorie rescue feeds.

12. Developmental delay after repeated, untreated episodes.

13. Hypothermia in neonates.

14. Occasional unconsciousness (syncope) in severe events.

15. No symptoms at all (hypoglycemia unawareness), especially if episodes are frequent—dangerous because warning signs fade.

(These features reflect the mixed autonomic and neuroglycopenic responses to low glucose seen in congenital hyperinsulinism.) endotext.org

---

Diagnostic tests

A) Physical examination (at the bedside)

1. General appearance and vital signs: look for sweating, pallor, tachycardia, low temperature, and irritability that improve with glucose—consistent with hypoglycemia. endotext.org

2. Neurologic exam: tone, reflexes, alertness; check for focal signs or seizure post-ictal states. endotext.org

3. Growth measures: weight/length/head circumference for effects of recurrent hypoglycemia and feeding patterns. endotext.org

4. Signs of dehydration or illness that could precipitate an episode (fever, infections). endotext.org

5. Feeding observation in infants: poor suck/coordination during lows and response after correction. endotext.org

B) “Manual” or bedside functional tests

6. Capillary glucose checks (frequent finger-sticks) during symptoms to document lows. endotext.org

7. Bedside ketone testing (blood β-hydroxybutyrate): suppressed ketones during hypoglycemia suggest hyperinsulinism. endotext.org

8. Glucagon response test at the bedside: IV/IM glucagon during a low should raise glucose if hepatic glycogen is available; a strong rise supports hyperinsulinism. endotext.org

9. Supervised fasting/tolerance assessment in hospital to learn how long the child can safely fast and to capture a “critical sample.” endotext.org

10. Continuous glucose monitoring (CGM) to reveal patterns, nocturnal lows, and response to therapy (useful adjunct). endotext.org

C) Laboratory and pathological tests (the “critical sample” work-up)

11. Plasma glucose (confirm in a lab sample) at the time of symptoms to anchor interpretation. endotext.org

12. Insulin and C-peptide during hypoglycemia: in hyperinsulinism, insulin is inappropriately detectable; C-peptide confirms endogenous secretion. endotext.org

13. β-hydroxybutyrate (ketones) and free fatty acids: both suppressed by high insulin during a low; a hallmark of HI. endotext.org

14. Response to IV glucagon (laboratory-documented rise in glucose) strengthens the diagnosis. endotext.org

15. Ammonia (to screen for GLUD1-related HI/HA as a differential) and lactate if atypical features—helps rule out other causes. endotext.org

16. Counter-regulatory hormones (cortisol, growth hormone) to exclude endocrine deficiencies that mimic HI. endotext.org

17. Genetic testing—ABCC8 sequencing ± deletion/duplication analysis: confirms a dominant ABCC8 variant and helps anticipate diazoxide responsiveness. Family testing informs recurrence risk. NCBI+1

18. In vitro functional studies (research settings) may be used to understand whether a new variant is likely diazoxide-responsive or not. PubMed

D) Electrodiagnostic and related monitoring

19. Electroencephalogram (EEG) if seizures occur—to document hypoglycemia-related epileptiform activity and guide anti-seizure management while glucose control is optimized. endotext.org

20. Electrocardiogram (ECG) and cardiorespiratory monitoring in severe neonatal cases—profound hypoglycemia can cause rhythm changes; monitoring improves safety during fasting studies. (Supportive critical-care practice around HI evaluation.) endotext.org

E) Imaging (used selectively)

• 18F-DOPA PET/CT of the pancreas to distinguish focal from diffuse disease and localize a focal lesion if suspected (particularly when diazoxide-unresponsive). This scan has transformed surgical planning in congenital hyperinsulinism. In dominant ABCC8 disease the pattern is usually diffuse, but PET is invaluable if the clinical picture is unclear. PubMed+2PMC+2

• Pancreatic ultrasound or MRI: usually limited for identifying focal lesions compared with PET, but may be used to exclude other pathology. PubMed

• Brain MRI in children with a history of severe or prolonged hypoglycemia to assess for injury and guide neurodevelopmental support. (General neurologic practice in HI follow-up.) endotext.org

Non-pharmacological treatments (therapies & other measures)

(Short, practical descriptions; I can expand any item to ~150 words on request.)

1. Immediate IV dextrose to treat acute episodes. Start a glucose infusion and titrate to keep plasma glucose ≥70 mg/dL; some infants need very high glucose infusion rates (occasionally 20–30 mg/kg/min). NCBI+1

2. Concentrated dextrose via central line. Use higher-strength dextrose (e.g., D20–D50) through a central line to avoid fluid overload when high GIR is required. NCBI

3. Frequent daytime feeds. Small, frequent feeds lower fasting time and reduce hypoglycemia risk, especially in infants and toddlers. NCBI

4. Overnight continuous enteral feeding when needed. Continuous feeds (via nasogastric/gastrostomy) can prevent nocturnal lows in children with limited fasting tolerance. NCBI

5. Uncooked cornstarch in older infants/children. Provides slow glucose release to prolong safe fasting intervals (specialist-guided). NCBI

6. Illness (sick-day) plan. During fevers/poor intake, lower fasting thresholds, increase monitoring, and escalate dextrose or feeds early to avoid severe lows. NCBI

7. Home glucose + ketone monitoring. Regular checks help families catch trends early; hypoglycemia in HI often shows suppressed ketones. NCBI

8. Emergency glucagon kit at home. Families should have rescue glucagon and know when/how to use it for severe symptoms while seeking help. FDA Access Data

9. Education and safety netting. Teach caregivers to recognize early symptoms (sleepiness, irritability, seizures) and to act quickly. Children’s Hospital of Philadelphia

10. Dietitian-guided nutrition. Age-appropriate calories/protein, careful carb spacing, and growth tracking reduce hypoglycemic swings. PMC

11. Avoid prolonged fasting. Individual fasting limits should be defined and updated as the child grows and gains fasting tolerance. NCBI

12. Neurodevelopmental follow-up. Early therapy (PT/OT/speech) if delays occur; preventing brain injury is the main goal of HI care. Congenital Hyperinsulinism International

13. Team-based care in experienced centers. Referral when persistent hypoglycemia, diazoxide non-response, or surgical evaluation is needed. PMC

14. 18F-DOPA PET-CT localization before surgery. Helps identify focal lesions that are curable with limited resection. PMC+1

15. Written school/caregiver plans. Clear orders for snacks, checks, and emergency steps reduce risks outside the hospital. Congenital Hyperinsulinism International

16. Fluid management around diazoxide use. Modest fluid restriction and careful monitoring may reduce pulmonary hypertension risk in neonates. Frontiers

17. Weaning protocols (glucagon/dextrose) once stable. Structured weans reduce rebound hypoglycemia and hospital length of stay. Pediatric Innovation Network

18. Genetic counseling for families. Explains dominant inheritance, recurrence risks, and screening of relatives. NCBI

19. Transition planning to home. Checklists for supplies, monitoring, rescue meds, and follow-up visits improve outcomes. Congenital Hyperinsulinism International

20. Psychosocial support. Coping with a chronic hypoglycemia disorder is hard; family support improves adherence and quality of life. Congenital Hyperinsulinism International

---

Drug treatments

Only diazoxide has an FDA label that directly references hyperinsulinism-related hypoglycemia in children; other agents are commonly used off-label in CHI. I’ll note standard dosing patterns briefly (clinicians individualize). Always follow specialist guidance. FDA Access Data+1

1. Diazoxide (oral). First-line if KATP channels are at least partly functional; opens KATP to suppress insulin release. Typical total dose 5–15 mg/kg/day divided BID–TID (stop if no response in 2–3 weeks). Watch for edema and rare neonatal pulmonary hypertension. PMC+1

2. Chlorothiazide (adjunct). Added to counter diazoxide-related fluid retention; typical 3–5 mg/kg/dose BID. Pediatric Innovation Network

3. Octreotide (SC/IV). Somatostatin analogue; lowers insulin secretion; used when diazoxide fails or is contraindicated. Short-acting dosing is individualized; monitor for GI effects and gallstones. FDA Access Data

4. Octreotide LAR (IM). Long-acting monthly formulation for maintenance in selected patients, often after stabilization on short-acting octreotide. FDA Access Data

5. Lanreotide (deep SC). Long-acting somatostatin analogue given every 4 weeks; used off-label in CHI when octreotide is unsuitable. FDA Access Data

6. Glucagon (IM/SC/IV). Rescue for severe hypoglycemia and continuous infusion in hospital to reduce dextrose needs by mobilizing hepatic glycogen. FDA Access Data+1

7. IV dextrose (various concentrations). Pharmacologic treatment in acute care; titrate GIR to maintain euglycemia; central line for higher concentrations. NCBI

8. Sirolimus (mTOR inhibitor). Considered in rare, refractory cases; case series show glucose stabilization but infection/mucosal and lipid adverse effects require close monitoring. New England Journal of Medicine+1

9. Everolimus (mTOR inhibitor). Similar rationale as sirolimus; limited CHI experience; used only in select refractory patients with strict risk–benefit discussion. PMC

10. Short-term nifedipine (calcium-channel blocker). Weak evidence and inconsistent response; not standard, but occasionally tried under specialist supervision. PMC

11. Hydrochlorothiazide (adjunct to diazoxide). Alternative thiazide to manage diazoxide fluid retention if chlorothiazide unavailable. Pediatric Innovation Network

12. Pasireotide. A newer somatostatin analogue with broader receptor binding; isolated reports in refractory hypoglycemia; monitor for hyperglycemia and liver effects. PMC

13. Continuous glucagon infusion (ICU). Useful “bridge” therapy when very high dextrose rates cause fluid overload; typical titration protocols are used in centers. Frontiers

14. Dextrose gel (buccal) in infants (hospital protocols). Can raise glucose transiently as a bridge to IV therapy or feeding; institutional guideline-based. eced.squarespace.com

15. Acarbose (selected older children). Slows carbohydrate absorption and may blunt postprandial swings in atypical, mild forms; evidence limited. NCBI

16. Glucocorticoids (not routine). Not standard for CHI but may be used transiently when other etiologies are considered; avoided long term. NCBI

17. Somatostatin infusion (short-term). Rarely used in monitored settings when analogues unavailable; risks include rebound hypoglycemia. FDA Access Data

18. Parenteral nutrition with glucose/lipids (bridge). For unstable cases when enteral feeds not possible, as part of ICU stabilization. NCBI

19. Magnesium supplementation (select cases). Correcting hypomagnesemia may help insulin regulation; only as clinically indicated. NCBI

20. Prophylaxis and monitoring for diazoxide adverse effects. Regular labs and clinical checks (glucose, ketones, uric acid, CBC, signs of pulmonary hypertension). FDA Access Data

Regulatory note: Among the above, the FDA label that directly references pediatric hyperinsulinism is diazoxide (PROGLYCEM); somatostatin analogues, glucagon, dextrose, and others are used off-label in CHI. Always interpret labels in context and follow specialist guidance. FDA Access Data+4FDA Access Data+4FDA Access Data+4

---

Dietary molecular supplements

There is no supplement that fixes the genetic channel defect. These options are supportive and must be individualized by a pediatric endocrine/dietitian team.

1. Uncooked cornstarch at bedtime to extend fasting time in older infants/children; dose is individualized (~0.5–1.5 g/kg), with glucose monitoring. NCBI

2. Maltodextrin (glucose polymers) added to feeds can increase caloric density and glycemic stability when supervised. Congenital Hyperinsulinism International

3. Protein-with-carb snacks to slow glucose dips between meals in mild, diazoxide-responsive forms. NCBI

4. Evening complex carbohydrates to reduce nocturnal lows with monitoring. NCBI

5. Electrolyte management (e.g., sodium limits) when on diazoxide + thiazide to reduce edema risk. FDA Access Data

6. Adequate iron and vitamin D for growth/brain health if deficient (not HI-specific but important in chronic pediatric illness). NCBI

7. Medium-chain triglyceride (MCT) additions to boost calories when volume-restricted; use with dietitian oversight. Congenital Hyperinsulinism International

8. Fiber timing (small amounts) to modulate glucose absorption in older children as tolerated. NCBI

9. Oral dextrose solution for rapid correction of mild symptomatic lows when IV not needed and per plan. eced.squarespace.com

10. Hydration planning around feeds/meds, especially if fluid restriction is temporarily required. Frontiers

---

Immunity booster / regenerative / stem-cell drugs

At this time, there are no FDA-approved “immunity boosters,” regenerative medicines, or stem-cell drugs for treating congenital hyperinsulinism due to SUR1 deficiency. Using such therapies outside a clinical trial would be speculative and potentially unsafe. Evidence-based care relies on glucose delivery, feeding strategies, diazoxide if responsive, somatostatin analogues, and rare use of mTOR inhibitors for refractory disease, with surgery for focal lesions. NCBI+2PMC+2

---

Surgeries

1. Focal lesionectomy (limited pancreatic resection). If 18F-DOPA PET-CT identifies a focal beta-cell lesion, limited surgery can be curative by removing the source of excess insulin. PMC+1

2. Sub-total pancreatectomy for diffuse, refractory disease. Considered only when maximal medical therapy fails; reduces insulin output but risks later diabetes and exocrine insufficiency. NCBI

3. Intraoperative frozen-section guidance. Helps confirm focal vs diffuse pathology during surgery to avoid unnecessary resection. PubMed

4. Peri-operative medication adjustments. Octreotide and glucagon are typically stopped before surgery to avoid confounding intraoperative assessment. Taylor & Francis Online

5. Post-operative glucose and enzyme monitoring. Watch for hyperglycemia (diabetes risk) or malabsorption; plan long-term endocrine follow-up. NCBI

---

Preventions

1. Never exceed your individual fasting limit without medical supervision. NCBI

2. Plan for illness (earlier feeds, higher monitoring frequency, low threshold for IV dextrose). NCBI

3. Carry fast-acting carbs and glucagon when away from home. FDA Access Data

4. Adhere to medication and lab monitoring schedules (especially with diazoxide). FDA Access Data

5. Use written care plans for school and caregivers. Congenital Hyperinsulinism International

6. Schedule regular endocrine + dietitian visits to adjust fasting limits and nutrition. PMC

7. Avoid unnecessary prolonged exercise or missed meals without pre-planning snacks. NCBI

8. Prompt evaluation after any seizure or severe low, even if recovered at home. NCBI

9. Consider center-of-excellence referral if diazoxide-unresponsive or surgery is considered. PMC

10. Family genetic counseling for recurrence-risk planning. NCBI

---

When to see a doctor (or go to the ER)

Seek urgent care for seizures, altered consciousness, persistent vomiting with inability to keep feeds down, or any glucose reading that stays low despite rescue treatment. Contact your endocrine team promptly for frequent lows, medication side effects (e.g., edema, breathing concerns on diazoxide), or if you approach planned fasting beyond your usual limit. FDA Access Data+1

---

What to eat — and what to avoid

Eat regular, evenly spaced meals with complex carbs and adequate protein; use bedtime slow-release carbs (e.g., cornstarch) if recommended. Avoid prolonged gaps between meals, unplanned strenuous activity without snacks, and very high-sugar spikes without a plan (these can be followed by lows). In illness, increase monitoring and consider more frequent feeds per your sick-day plan. NCBI

---

Frequently asked questions (FAQ)

1) Can autosomal dominant ABCC8 HI get better over time?
Yes. Many dominant cases improve as fasting tolerance increases with age, though some patients continue to need treatment. Long-term follow-up is important. NCBI

2) How is dominant ABCC8 different from recessive KATP HI?
Dominant disease is often milder, may present later, and is more often diazoxide-responsive; recessive neonatal forms are typically severe and may need surgery. NCBI

3) Why are ketones low during a low sugar episode?
Excess insulin blocks fat breakdown and ketone production, removing brain backup fuels and raising neuroglycopenia risk. NCBI

4) Is diazoxide safe for infants?
It’s widely used but requires careful monitoring for edema, hyperuricemia, and rare pulmonary hypertension; stop if no response in 2–3 weeks. FDA Access Data

5) When do doctors use octreotide or lanreotide?
If diazoxide fails or is not tolerated. These somatostatin analogues suppress insulin but are off-label for CHI and need monitoring for GI and gallbladder effects. FDA Access Data+1

6) What is 18F-DOPA PET-CT and why is it important?
It localizes focal lesions that can be cured by limited surgery, avoiding near-total pancreatectomy in many infants. PMC

7) Are mTOR inhibitors a cure?
No. Sirolimus/everolimus can stabilize refractory cases but carry infection, mucositis, lipid, and other risks; they’re reserved for select patients. New England Journal of Medicine+1

8) Can supplements cure CHI?
No. They may help stabilize glucose between meals (e.g., cornstarch in older children), but they do not fix the channel defect. NCBI

9) Will my child develop diabetes later?
Risk depends on genetics and any surgery performed; those with large pancreatic resections have a higher diabetes risk later in life. NCBI

10) Is continuous glucose monitoring (CGM) used?
Some centers use CGM off-label to aid trend recognition, but confirm w/ fingersticks during treatment decisions. PMC

11) What glucose level is “safe”?
Teams usually aim to keep plasma glucose ≥70 mg/dL and avoid lows entirely in infants/young children to protect the brain. NCBI

12) How long can my child safely fast?
It’s individualized and increases with age; your team will test and document safe fasting intervals. NCBI

13) Why do we carry glucagon if insulin is the problem?
Glucagon rapidly releases liver glucose stores to reverse dangerous hypoglycemia until medical care or feeding is given. FDA Access Data

14) If diazoxide works, how long do we use it?
Treatment continues until the child outgrows the need; clinicians reassess fasting tolerance and may taper when safe. NCBI

15) When is surgery considered?
When medical therapy fails, or when 18F-DOPA PET-CT shows a focal lesion suitable for curative resection. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.